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Abstract
Knowledge of the mechanisms for regulating lifespan is advancing rapidly, but lifespan is a complex phenotype and new
features are likely to be identified. Here we reveal a novel approach for regulating lifespan. Using a genetic or a
pharmacological strategy to lower the rate of sphingolipid synthesis, we show that Saccharomyces cerevisiae cells live
longer. The longer lifespan is due in part to a reduction in Sch9 protein kinase activity and a consequent reduction in
chromosomal mutations and rearrangements and increased stress resistance. Longer lifespan also arises in ways that are
independent of Sch9 or caloric restriction, and we speculate on ways that sphingolipids might mediate these aspects of
increased lifespan. Sch9 and its mammalian homolog S6 kinase work downstream of the target of rapamycin, TOR1, protein
kinase, and play evolutionarily conserved roles in regulating lifespan. Our data establish Sch9 as a focal point for regulating
lifespan by integrating nutrient signals from TOR1 with growth and stress signals from sphingolipids. Sphingolipids are
found in all eukaryotes and our results suggest that pharmacological down-regulation of one or more sphingolipids may
provide a means to reduce age-related diseases and increase lifespan in other eukaryotes.
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Introduction
Most of us dream of a long life and wonder if we can increase
our time on earth. Except for caloric restriction (CR), there has
been little prospect for increasing lifespan. But recent studies offer
hope for developing drugs that increase lifespan by reducing the
incidence of age-related diseases that kill most humans. The
immunosuppressant drug rapamycin has been shown to reduce
age-related diseases and increase lifespan in yeasts, flies and mice
[1–3] and these results have stimulated searches for new ways to
enhance lifespan [4–6]. Here we introduce a novel strategy to
extend the lifespan of Saccharomyces cerevisiae cells that involves
reducing the rate of sphingolipid synthesis. This strategy increases
lifespan at least partly by reducing the activity of the Sch9 protein
kinase, a homolog of mammalian ribosomal S6 kinase, both of
which regulate lifespan and function downstream of the target of
rapamycin (TOR) protein kinase, a well established and
evolutionarily conserved regulator of lifespan [7–10].
Sphingolipids are recognized as structural components of
eukaryotic membranes and as signaling molecules for regulating
cell growth and migration, differentiation, apoptosis, senescence
and inflammation [11–13]. This wide range of functions arises
from the variation in carbon chain length, degree and location of
unsaturation and hydroxylation along with other modifications of
the long-chain bases (LCBs) and fatty acids that are amide-linked
to each other to form ceramides, to which polar groups are
attached to form complex sphingolipids [14]. Variation in polar
head groups further expands the types of sphingolipids found in
nature and implies that many more functions await discovery.
Although yeast sphingolipids (Figure S1 in Text S1) lack the
complexity of those in mammals, S. cerevisiae has, nevertheless,
been vital in identifying sphingolipid metabolic genes and in
understanding sphingolipid functions [15–17].
Studies in yeast, worms, flies and mice establish the TOR
pathway as a vital regulator of aging and lifespan [1,2,8,10,18,19].
Eukaryotes have two types of TOR complexes and TOR complex 1
(TORC1) regulates lifespan. Yeast TORC1 phosphorylates serine
and threonine residues in the C-terminus of Sch9 (Figure 1A) [20]
while an additional residue, T570, in the activation loop of the
kinase domain must be phosphorylated also for Sch9 to be active
[20,21]. Residue T570 is phosphorylated by the redundant Pkh1
and Pkh2 protein kinases, homologs of mammalian phosphoinosi-
tide-dependent protein kinase 1 (PDK1) [20–22].
Dual regulation of Sch9 provides a way to monitor environmen-
tal and cellular cues and integrate them with multiple biological
processes necessary for growth and survival. TORC1 senses and is
activated by nutrients, particularly amino acids, and growth factors
to promote biosynthetic processes such as protein synthesis [10,23].
In contrast, nutrient depletion or environmental stresses reduce
TORC1 activityandbiosyntheticprocessesbecomelessactivewhile
catabolicprocesses,suchasautophagy,becomemore activeinorder
to salvage nutrients and reduce their consumption. Pkh1/2 are also
involved in nutrient and stress signaling and activate not only Sch9
(Figure 1A), but also the Ypk1 and Ypk2 protein kinases (homologs
of mammalian serum and glucocorticoid-inducible kinase, SGK),
Pkc1 and PKA thereby controlling many cellular processes
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and stress resistance [15,16,24,25].
Sphingolipids are known activators of Pkh1/2 [15,16,26,27]
and we posit that they ought to regulate lifespan by controlling the
activity of the Pkh1/2-Sch9 pathway. By lowering the rate of
sphingolipid biosynthesis, we demonstrate enhancement of
chronological lifespan (CLS), a measure of how long non-dividing
cells survive in stationary phase. The increase in lifespan is due to
Sch9-dependent and independent processes that are also con-
trolled by sphingolipids.
Results
Genetic strategy for down-regulating sphingolipid
synthesis
In one strategy to determine if sphingolipids regulate CLS we
used a tetracycline-repressible promoter cassette (tetO7) to regulate
gene transcription [28]. The utility of this strategy for studying
CLS was verified by using cells having transcription of the SCH9
gene (tetO7-SCH9) or the RIM15 gene (tetO7-RIM15) controlled by
the tetO7 promoter. Based on the roles of Sch9 and Rim15 in
lifespan [7], we expected CLS to increase in doxycycline (Dox)-
treated tetO7-SCH9 cells and to decrease in Dox-treated tetO7-
RIM15 cells. We find that a low concentration of Dox (100 ng/ml)
significantly increases the CLS of tetO7-SCH9 cells (Figure 1B)
while a higher dose of Dox (1000 ng/ml) is needed to decrease the
CLS of tetO7-RIM15 cells (Figure 1C). In control experiments we
find that Dox treatment has no effect on the CLS of the parental
strain R1158 (Figure 1B and 1C, WT). Thus, this experimental
strategy is able to recapitulate the CLS phenotype of sch9D and
rim15D mutant cells. It also recapitulates the increased oxidative
stress resistance of sch9D cells and the reduced resistance of rim15D
cells [7] (Figure 1D).
Down-regulating tetO7-LCB1 and tetO7-LCB2 increases
CLS
The essential LCB1 and LCB2 genes encode subunits of serine
palmitoyltransferase (SPT), the first and rate-limiting enzyme in
sphingolipid biosynthesis (Figure S1 in Text S1) [15] and we
expected that by lowering expression of LCB1 or LCB2 it should
be possible to lower the level of sphingolipids and extend lifespan
via reduction of the sphingolipid-controlled Pkh1/2-Sch9 path-
way. We identified concentrations of Dox that reduce the initial
rate of growth but not the final cell density of strains with tetO7-
LCB1 or tetO7-LCB2 alleles, consistent with a lowered rate of
sphingolipid synthesis but not low enough to affect the final cell
density or mass yield (Figure 2A and 2B). Under these conditions
Dox-treated and untreated cells should be in a similar metabolic
state upon entering stationary phase and any effect of Dox on
lifespan should be due to down-regulation of LCB1 or LCB2
rather than to off target effects.
We find that the CLS of tetO7-LCB1 or tetO7-LCB2 cells treated
with 100 or 300 ng/ml of Dox increases significantly (Figure 2C
and 2D). Control experiments demonstrate that this increase in
CLS is due to down-regulation of LCB1 or LCB2 and not to off
target effects of Dox. First, Dox treatment has no effect on the
CLS of wild-type R1158 cells, the parent of tetO7-LCB1 and tetO7-
LCB2 cells (Figure 1B and 1C). Next, we reasoned that
introduction of a plasmid-borne wild-type LCB1 gene into tetO7-
LCB1 cells should preclude Dox from increasing CLS, since the
wild-type LCB1 allele will not respond to Dox and SPT activity
should be normal. As expected, the CLS of Dox-treated tetO7-
LCB1 cells transformed with a single-copy vector carrying the
LCB1 gene is reduced compared to cells transformed with just the
vector and is similar to cells not treated with Dox (Figure 2E).
Analogous experiments with tetO7-LCB2 cells give similar results
(Figure 2F). We conclude from these data that Dox treatment of
cells carrying a tetO7-LCB1 or tetO7-LCB2 allele increases CLS
because expression of the LCB1 or LCB2 gene is reduced.
Finally, most experimental manipulations enhance lifespan in
part by increasing stress resistance. Thus we anticipated that
down-regulating the tetO7-LCB1 or tetO7-LCB2 genes by Dox
treatment would increase stress resistance and, indeed, resistance
to heat and hydrogen peroxide stress did increase (Figure 2G).
Myriocin treatment increases CLS
A second strategy for determining if sphingolipids regulate CLS
uses myriocin, an inhibitor of SPT, to down-regulate enzyme
activity. We examined the effect of low doses of myriocin on three
strains: DBY746, used extensively to study CLS [7], BY4741, the
parent of one of the non-essential yeast gene deletion sets which is
often used to study lifespan [8], and a derivative of BY4741,
R1158, the parent strain for making tetO7-regulated genes [28].
The initial rate of R1158 cell growth is the least impaired by
myriocin treatment while growth of DBY746 and BY4741 cells is
more impaired (Figure 3A, 3C and 3E). The highest concentration
of myriocin used for each strain causes a delay in initial cell growth
and increases the time it takes for DBY746 and BY4741 cells to
enter stationary phase. However, the final cell density is either the
same as or within 20% of the cell density found in the absence of
drug, which argues that differences in final cell density or failure to
enter stationary phase are not likely to explain the effect of
myriocin on CLS. Using these same drug concentrations, there is a
robust, dose-dependent and statistically significant increase in the
CLS of each strain (Figure 3B, 3D and 3F) with DBY746 cells
showing the largest increase (Figure 3B). DBY746 cells treated
with 400 ng/ml of myriocin grow slowly and, unlike the other
cells, do not stop growing at 72 hrs (CLS day 1), but keep growing
up to about the 120 hr time point. This causes an increase in
viable cells on CLS days 3 and 6 (Figure 3B, solid red line) and
overstates the increase in CLS. To compensate for this extended
growth phase, we set the 120 hr time point as CLS day 1
Author Summary
Studies with rats in the 1930s showed a surprising increase
in lifespan when the diet contained 30%–40% fewer
calories than normal. This experiment has been repeated
on many organisms and is the gold standard for extending
lifespan. While we are beginning to understand how
calorie restriction regulates lifespan, the mechanisms are
complex and much remains to be learned. In the work
presented here, we demonstrate a novel way to increase
lifespan in the budding yeast Saccharomyces cerevisiae.
Our strategy is to lower the rate of sphingolipid synthesis
either by reducing the synthesis of the first enzyme in the
biosynthesis pathway or by using a drug to reduce enzyme
activity. This strategy works in part by lowering the activity
of a protein kinase, termed Sch9 in yeast and S6K in
mammals, both of which are involved in the processes
affected by calorie restriction and that control lifespan. In
addition, we find that reducing sphingolipid synthesis
increases lifespan in ways that are independent of Sch9
and calorie restriction. Since sphingolipids are found in all
eukaryotes, our results suggest that pharmacological
down-regulation of one or more sphingolipids may
provide a means to reduce age-related diseases and
increase lifespan in other eukaryotes.
Sphingolipids Control Lifespan
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corrected survival curve still shows an increase in lifespan
(Figure 3B, dashed red line), but not as large an increase as the
uncorrected curve (Figure 3B, solid red line).
Myriocin treatment, similar to down-regulation of LCB1 or
LCB2 expression, increases resistance of DBY746 cells to both heat
and hydrogen peroxide stress (Figure 3G). In summary, the data
presented in Figure 3 provide additional and independent support
for the hypothesis that sphingolipids regulate stress resistance and
CLS.
Wild-type yeast cells normally grow to a specific size, but
mutation of SCH9 has the unusual effect of reducing cell size [29].
If a reduction in sphingolipid synthesis increases CLS by reducing
Sch9 activity as we predict (Figure 1A), then cell size ought to be
reduced. We find that the volume of myriocin-treated DBY746
cells on CLS day 1 is 28% lower than that of untreated cells
(Figure S2 in Text S1, 59 verses 82 mm
3). This reduction is less
than the 40% reduction reported for sch9D cells compared to wild-
type DBY746 cells [30], but probably reflects just a partial
reduction of Sch9 activity in myriocin-treated cells (see below)
compared to no activity in sch9D cells.
Acetic acid accumulation in the diauxic shift has been proposed
as a major cause of cell death, but it can be alleviated by buffering
the medium [31]. To eliminate the possibility that myriocin
treatment extends CLS by preventing acetic acid killing, we
compared the effect of myriocin treatment in buffered and
unbuffered medium. Medium was buffered with succinate
(200 mM), pH 4.5, because this compound is not metabolized
by yeast cells. Myriocin treatment extended CLS in either buffered
or unbuffered media (Figure 3H). Thus, myriocin treatment does
not extend lifespan simply by increasing resistance to acetic acid
and additional support for this conclusion is provided below. Also,
we found that the rate of cell death increased because the
concentration of iron (1.23 mM) in SDC medium was limiting and
we added 3-fold more iron to the medium (indicated in figure
legends) to eliminate this variable. The succinate-buffered medium
Figure 1. The tetO7 promoter can be used to regulate CLS. (A) Model showing how sphingolipids are proposed to regulate lifespan. In this
model LCBs and perhaps other sphingolipids activate the Pkh1 and Pkh2 protein kinases which phosphorylate residue T570 in the activation loop of
the Sch9 protein kinase. Activation of Sch9 also requires phosphorylation of C-terminal residues by the TORC1 kinase. Ceramide-mediated activation
of the Sit4 protein phosphatase may also play roles in regulating lifespan as outlined in the Discussion. (B) CLS of tetO7-SCH9 (RCD952) and WT
(R1158) cells +/2 Dox treatment. Data show the mean 6 SEM of surviving cells (** p,0.01, No Dox vs Dox treatment). Triplicate cultures were used in
these and all other CLS experiments. (C) CLS of tetO7-RIM15 (RCD994) and WT (R1158) cells +/2 Dox treatment. Data show the mean 6 SEM of
surviving cells (* p,0.05, ** p,0.01, No Dox vs Dox treatment). (D) Oxidative stress (H2O2) resistance of cells from CLS day 1. Strains are: WT, R1158;
tetO7-SCH9, RCD952; tetO7-RIM15, RCD994.
doi:10.1371/journal.pgen.1002493.g001
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PLoS Genetics | www.plosgenetics.org 3 February 2012 | Volume 8 | Issue 2 | e1002493Figure 2. Down-regulating sphingolipid synthesis increases CLS. (A) Growth rate of tetO7-LCB1 cells (RCD956) treated with Dox to down-
regulate expression of the tetO7 promoter and reduce the rate of sphingolipid synthesis. (B) Growth rate of tetO7-LCB2 cells (RCD957) +/2 Dox
treatment. (C) CLS of tetO7-LCB1 cells +/2 Dox treatment. Data show the mean 6 SEM of surviving cells (* p,0.05, ** p,0.01, No Dox vs 100 ng/ml
Dox). (D) CLS of tetO7-LCB2 cells +/2 Dox treatment. Assays are similar to those presented in (C). (E) Verification that Dox-treatment extends CLS by
reducing expression of the tetO7-LCB1 target gene. CLS of tetO7-LCB1 cells transformed with an empty vector (Vec1=pRS315ADE2) or a vector
carrying LCB1 (pLCB1=pRS315ADE2-LCB1-5) is shown. Data represent the mean 6 SEM of surviving cells (* p,0.05, ** p,0.01, for Vec1, 100 ng/ml
Sphingolipids Control Lifespan
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noted before [32], since we found that reducing the concentration
from 200 to 50 mM caused a slight reduction in CLS, but no
change in pH during the assay. The low pH of this medium is
advantageous because the solubility of iron increases greatly at
lower pHs [33].
Down-regulating LCB1 or SPT lowers sphingolipid levels
If sphingolipids mediate increased CLS, then we predict that
down-regulating tetO7-LCB1 expression by Dox treatment or
reducing SPT activity by myriocin treatment should lower
sphingolipid levels. We measured LCBs, made primarily as
intermediates in the de novo sphingolipid synthesis pathway, as
well as the terminal complex sphingolipids found primarily in
the plasma membrane. We also measured LCBPs made by
phosphorylation of LCBs and thought to primarily represent
intermediates in the degradation of LCBs (Figure S1 in Text
S1).
We find that Dox treatment of tetO7-LCB1 cells, grown the same
way as in a CLS assay, reduces total LCBs (C16-, C18- and C20-
dihydrosphingosine and C18- and C20-phytosphingosine) by 84%
with individual species of LCBs responding uniquely to drug
treatment (Figure 4A). The much less abundant LCBPs are also
reduced in toto by about 70% (Figure 4A). Dox treatment of wild-
type R1158 cells does not produce a statistically significant change
in the level of LCBs and LCBPs (data not shown).
Similarly, myriocin treatment of DBY746 cells, grown in the
same way as in a CLS assay, reduces total LCBs by 64% and total
LCBPs 62% (Figure 4B).
Next, we examined the effect of down-regulating sphingolipid
synthesis on complex sphingolipids including inositol-phosphocer-
amide (IPC), mannose-inositol-phosphoceramide (MIPC) and
mannose-(inositol-P)2-ceramide (M(IP)2C) (Figure S1 in Text S1).
There is a statistically significant reduction in IPCs in both Dox
treated tetO7-LCB1 cells and myriocin-treated DBY746 cells
(Figure 4C, 4D and 4E). Because MIPCs are not well separated
from IPCs (Figure 4C), both types of sphingolipids, not just IPCs,
may be reduced in drug-treated cells. There is a tendency for
M(IP)2Cs to decrease in Dox-treated tetO7-LCB1 cells but to
increase in myriocin-treated DBY746 cells. However, neither
change is statistically significant, suggesting that M(IP)2Cs are not
playing roles in CLS. Our data show that down-regulating the rate
of sphingolipid synthesis by impairing activity of the first enzyme
in the biosynthesis pathway lowers the concentration of LCBs,
LCBPs, IPCs and perhaps MIPCs and some or all of these changes
could influence CLS.
Pkh2 regulates CLS
As further support for our hypothesis that sphingolipids
regulate CLS by controlling the Pkh1/2-Sch9 signaling pathway,
we sought to show that PKH1 or PKH2 or both genes regulate
CLS. Recently, deletion of PKH2 in the diploid BY4743 strain
background was shown to produce a small but significant increase
in CLS [34]. To verify these data and extend them to a haploid
strain background and culture conditions with a different pH and
buffering ions, we measured the CLS of a pkh2D mutant made in
the R1158 strain background. We find a small but statistically
significant increase in the CLS of pkh2D cells (Figure 5A). Our
data are very similar to results obtained with BY4743 cells where
the mean survival interval (area under a survival curve) was 3.10
for wild-type cells compared to 4.05 (34% increase) for pkh2D
cells whereas our values are 4.14 verses 5.23 (29% increase).
Together, the published data and our data establish a role for
Pkh2 in regulating CLS.
Phosphorylation of residue T570 in Sch9 is critical for protein
kinase activity and is mediated in vivo and in vitro by Pkh1/2
[20,25] and is stimulated by LCBs [21]. If Pkh1/2 regulate Sch9
activity by phosphorylating residue T570, we anticipate less
phosphorylation in pkh2D cells, since this would reflect reduced
Sch9 activity and would explain the increase in CLS of pkh2D cells.
We find a statistically significant 20% reduction of T570
phosphorylation in pkh2D cells compared to wild-type PKH2 cells
which supports the hypothesis that Pkh2 phosphorylates this key
Sch9 residue (Figure 5B and 5C).
Another prediction of the proposed signaling pathway going
from sphingolipids to Pkh1/2 to Sch9 and other downstream
kinases (Figure 1A) is that growth of cells with a low level of Pkh
kinase activity ought to be more sensitive to myriocin (reduced
SPT activity) compared to cells with a higher level of kinase
activity if sphingolipids regulate Pkh activity. Comparison of the
myriocin sensitivity of cells with varying combinations of mutant
and wild-type PKH1 and PKH2 alleles shows that cells with a
temperature-sensitive PKH1 allele or a deletion allele are very
sensitive to myriocin at a permissive temperature compared to cells
with PKH1 or PKH2 or both wild-type genes (Figure 5D). Likewise,
deletion of either gene in a tetO7-LCB1 strain reduces Pkh activity
and increases sensitivity to myriocin (Figure S4A in Text S1),
moreover, Dox treatment further reduces Pkh activity by lowering
sphingolipid levels and impairs growth compared to the parent
tetO7-LCB1 (PKH1 PKH2) strain (Figure S4B in Text S1). These
data all support the proposed role of sphingolipids as upstream
activators of the Pkh1/2 kinases.
Sphingolipids control phosphorylation of Sch9-T570 and
Sch9 substrates
To explore further the hypothesized role of sphingolipids in
regulating CLS via the Pkh1/2-Sch9 signaling pathway, we
examined phosphorylation of Sch9 residue T570. If sphingolipids
control T570 phosphorylation, then reducing SPT activity by
myriocin treatment or by Dox treatment of tetO7-LCB1 cells
should decrease phosphorylation. Cells were grown as in a CLS
assay, but because drug-treated cells grow slower than untreated
cells, comparisons were made with cells grown to similar A600 nm
values (,1) rather than for similar times.
We find a statistically significant 35% reduction in T570
phosphorylation in log phase DBY746 cells treated for 7–8 cell
doublings with myriocin compared to untreated cells (Figure 5E
and 5F, n=4 cultures). Also, in parental R1158 (LCB1) and tetO7-
LCB1 cells myriocin treatment reduces T570 phosphorylation by
40% (Figure 5G, compare lane 1 with 2 and lane 3 with 4). Lastly,
there is a 40% reduction in T570 phosphorylation in Dox-treated
tetO7-LCB1 cells (Figure 5H, compare lanes 3 and 4) but no effect
in parental R1158 cells, as expected since LCB1 is not regulated by
the tetO7 promoter (Figure 5H, compare lanes 1 and 2). These data
Dox vs pLCB1, 100 ng/ml Dox). (F) Control experiment showing that Dox-treatment extends CLS by reducing expression of the tetO7-LCB2 gene. CLS
of tetO7-LCB2 cells transformed with a vector carrying LCB2 (pLCB2=pRS315-LCB2-B7) or with an empty vector (Vec2=pRS315) is shown. Data
represent the mean 6 SEM of surviving cells (* p,0.05, ** p,0.01, for Vec2, 100 ng/ml Dox vs pLCB2, 100 ng/ml Dox). (G) Resistance of Dox-treated
WT (R1158), tetO7-LCB1 (RCD956) and tetO7-LCB2 (RCD957) cells to heat (55uC) or hydrogen peroxide (H2O2) stress. Photographs show a ten-fold
dilution series of cells (from left to right).
doi:10.1371/journal.pgen.1002493.g002
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PLoS Genetics | www.plosgenetics.org 6 February 2012 | Volume 8 | Issue 2 | e1002493support the hypothesis that down-regulating sphingolipid levels by
genetically or pharmacologically lowering SPT activity reduces
T570 phosphorylation and consequently Sch9 activity thereby
promoting increased CLS.
In all cases examined (Figure 5E, 5G and 5H), the total level of
Sch9 protein is not changed by drug treatment. However, drug
treatment does cause a shift of the Sch9 band to a slightly faster
migrating form, similar to what is seen when phosphorylation of
Sch9 is reduced [20]. In the case where Pkh activity was reduced
by deleting PKH2 rather than by down-regulating sphingolipid
synthesis, there was no shift in the mobility of Sch9 to a faster
migrating form even though phosphorylation of T570 decreased
(Figure 5B). Thus, the band shift we observe suggests that a
reduction in sphingolipids triggers dephosphorylation of other
Sch9 amino acid residues in addition to T570 and further work
will be required to identify the residues involved.
The effect of myriocin treatment on the phosphorylation level of
the Sch9 substrate Dot6 was also examined. Sch9 regulates
ribosome biogenesis in part by phosphorylating transcriptional
repressor proteins including Dot6, Tod6 and Stb3 [35,36]. Dot6
controls transcription of ribosome biogenesis [37] genes that are
essential for ribosome formation. We find that Dot6-5HA in
myriocin-treated cells migrates faster on a denaturing gel than it
does in untreated cells (Figure 5I), indicating reduced phosphor-
ylation by Sch9 [36]. To directly demonstrate reduced Sch9
activity in these myriocin-treated cells, the blot shown in Figure 5I
was reprobed for T570 phosphorylation. As found in other
myriocin-treated cells, there was a reduction in T570 phosphor-
ylation and an increase in Sch9 mobility, both indicative of
reduced Sch9 activity (Figure 5J). Together, the data shown in
Figure 5 demonstrate that down-regulating sphingolipid synthesis
by treatment of cells with myriocin or Dox reduces Sch9 activity.
Reduced activity is at least partly responsible for the increase in
CLS we observe in drug-treated cells (Figure 2, Figure 3, and
Figure 7).
Down-regulating sphingolipid synthesis enhances CLS by
Sch9-dependent and -independent mechanisms
Part of the mechanism for increased CLS in sch9D cells is
greater resistance to oxidative, heat and acetic acid stress [7,31]. If
sphingolipids are regulating CLS by Sch9-dependent mechanisms,
then reducing the rate of sphingolipid synthesis should increase
stress resistance. Indeed, resistance to heat and oxidative stress do
increase (Figure 2G and Figure 3G) as does resistance to acetic
acid when tetO7-LCB1 cells are treated with Dox, and resistance is
nearly as robust as in sch9D cells (Figure 6A). Likewise, treating
DBY746 cells with myriocin increases resistance to acetic acid
albeit resistance is not enhanced as much as in sch9D cells
(Figure 6B). These data support the hypothesis that sphingolipids
regulate CLS by Sch9-dependent mechanisms.
Deletion of SCH9 is known to extend CLS by enhancing
respiration [38,39]. To determine if myriocin treatment also
extends CLS by inducing respiration we measured oxygen
consumption. We find a more than 2-fold, statistically significant
increase in oxygen consumption in myriocin-treated cells com-
pared to untreated cells (Figure 6C). In contrast, there is no
statistically significant stimulation of oxygen consumption in sch9D
cells treated with myriocin, indicating that Sch9 mediates most if
not all of the effect of myriocin on oxygen consumption
(Figure 6C).
Sch9 also affects aging and lifespan by controlling genome
stability [40,41]. For example, sgs1D cells display premature age-
dependent genome instability that is prevented by deletion of
SCH9 [42]. Sgs1 is a member of the RecQ helicase family of DNA
unwinding proteins which maintain genome stability. Sgs1 is
related to human RecQ helicases WRN, defective in the
premature aging disorder Werner’s syndrome, and BLM, defective
in the cancer-prone disorder Blooms’ syndrome [42]. If sphingo-
lipids control Sch9 activity, then age-dependent genome instability
in a sgs1D strain should be prevented by treating cells with
myriocin.
Genome instability was quantified by measuring the frequency
of Can
r mutations. As in previous studies [42], we find Can
r
mutations accumulating at a faster rate in sgs1D cells during
chronological aging and by day 12 they are 4-fold more abundant
than in wild-type cells (Figure 6D). Deletion of SCH9 reverses the
effect of the sgs1 mutation since cultures of sgs1D sch9D cells have
fewer Can
r mutants than the wild-type cultures. Notably, treating
sgs1D cells with myriocin reduces the frequency of Can
r mutants to
the wild-type level at all times during a CLS assay (Figure 6D).
In a second assay of genome instability the frequency of gross
chromosomal rearrangements (GCRs) was measured [42]. By day
12 there are five times more GCRs in sgs1D cells than in wild-type
or sgs1D sch9D cells (Figure 6E). Again, myriocin treatment reduces
the frequency of GCRs about 75% at day 12 in sgs1D cells, very
similar to the reduction obtained by deleting SCH9 (sgs1D sch9D
cells, Figure 6E). In summary, the data presented in Figure 6
support the hypothesis that sphingolipids regulate CLS by Sch9-
dependent mechanisms.
Finally, if myriocin enhances CLS entirely by mechanisms
requiring Sch9, then myriocin should not enhance CLS in sch9D
cells. We find that a dose of 25 or 100 ng/ml myriocin has no
effect on the CLS of sch9D cells, but a higher dose of 300 ng/ml
produces a statistically significant increase in CLS starting around
day 22 (Figure 7A). Thus, myriocin most likely extends CLS in the
early and middle time-frame of a CLS assay by Sch9-dependent
mechanisms, but at later times the enhancement in lifespan is
independent of Sch9. Possible mechanisms for the Sch9-indepen-
dent effects on CLS are presented in the Discussion.
Down-regulating sphingolipid synthesis extends CLS in
caloric-restricted cells
Since calorie restriction increases the CLS of sch9D cells [30],
we determined if myriocin produces an effect similar to CR. CR
Figure 3. Myriocin treatment extends CLS. (A) Growth rate of DBY746 cells +/2 myriocin (Myr) treatment. Myriocin (300 ng/ml) treatment
reduces cell size and there are fewer cells/A600 nm in the treated than in the untreated cultures (1.6610
7 cells/A600 nm in treated cultures verses
1.8610
7 cells/A600 nm in untreated cultures). (B) CLS of DBY746 cells treated as described in (A). Data represent the mean 6 SEM of surviving cells (*
p,0.05, ** p,0.01, No Myr vs 200 and 400 ng/ml Myr). To compensate for the slow growth and extended growth phase of cells treated with 400 ng/
ml of myriocin (solid red line), the viability at the 120 hr time point, CLS day 3, was set as CLSday1 (dashedredline).(C) GrowthrateofR1158cells+/2
myriocin (Myr) treatment. Cells/A600 nm unit are similar to those described in (A). (D) CLS of R1158 cells treated as described in (C). Data represent the
mean 6 SEM of surviving cells (* p,0.05, ** p,0.01, two-tailed t-test for No Myr vs 400 ng/ml Myr). (E) Growth rate of BY4741 cells +/2 myriocin (Myr)
treatment. (F) CLS of BY4741 cells incubated as described in (E). Data represent the mean 6 SEM of surviving cells (* p,0.05, ** p,0.01, No Myr vs
600 ng/mlMyr). (G) Resistanceof myriocin-treated DBY746 cells to heat (55uC) or hydrogenperoxide(H2O2) stress.Photographs show a ten-folddilution
seriesof cells(from left toright). (H)CLSof DBY746cells grownin SDCmediumbufferedto pH 6 or 4.5 +/2 myriocin (Myr)treatment.Datarepresent the
mean 6 SEM of surviving cells (* p,0.05, ** p,0.01, No Myr vs 300 ng/ml Myr).
doi:10.1371/journal.pgen.1002493.g003
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PLoS Genetics | www.plosgenetics.org 7 February 2012 | Volume 8 | Issue 2 | e1002493Figure 4. Myriocin or Dox treatment reduces sphingolipid levels. (A) LCBs and LCBPs were quantified in cells grown from an A600 nm of 0.005
to 1 in the presence of absence of Dox (300 ng/ml). Average values for triplicate cultures of tetO7-LCB1 (RCD956) cells are shown (* p,0.05,
** p,0.01, *** p,0.001, No Dox vs Dox-treated). (B) LCBs and LCBPs were quantified in DBY746 cells treated or not treated with Myr (400 ng/ml)
grown the same way as in (A). Average values for triplicate cultures are shown (* p,0.05, ** p,0.01, *** p,0.001, No Myr vs Myr-treated). (C)
Complex sphingolipids (IPCs, MIPCs and M(IP)2Cs) in untreated and Dox-treated RCD956 cells were grown as in (A) in the presence of [
3H]-myoinositol
and cpm were quantified by scanning the thin-layer chromatogram on a Bioscan apparatus. Glycerol –P-inositol represents the deacylation product
of phosphatidylinositol and serves as an internal control. (D) Average cpm +/2 SD for [
3H]-labeled lipids from three cultures analyzed as in (C). (E)
Average cpm +/2 SD for [
3H]-labeled lipids from three cultures of DBY746 cells treated or not treated with Myr (400 ng/ml). Cells were grown and
analyzed as in (C).
doi:10.1371/journal.pgen.1002493.g004
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PLoS Genetics | www.plosgenetics.org 9 February 2012 | Volume 8 | Issue 2 | e1002493was implemented by switching cells on day 3 from culture
medium to water. This extreme form of CR was used because it
prevents adaptive regrowth and eliminates regrowth as an
explanation for myriocin-induced CLS extension [40]. We find
that myriocin produces a dose-dependent increase in the CLS of
cells subjected to extreme CR (Figure 7B). Thus, myriocin
extends CLS in sch9D cells similar to CR treatment, extends CLS
even under conditions where adaptive regrowth does not occur,
and programs cells for an extended lifespan prior to the end of
the diauxic shift (prior to shifting cells to water). In addition, these
data further support the conclusion that myriocin does not simply
extend CLS by protecting cells from acetic acid killing, since
replacing the culture medium with water and changing the water
every third day eliminates acetic acid accumulation. Finally, we
find that myriocin also enhances CLS when CR is applied by
reducing the concentration of glucose from 2 to 0.5% (Figure S3
in Text S1).
Discussion
The desire for a long and healthy life is universal, but most of us
will succumb sooner than hoped for due to age-related disorders,
particularly cancer, cardiovascular disease and diabetes. Fortu-
nately, strategies that enhance lifespan in model organisms work to
a large degree by delaying the onset of these diseases. A striking
example of this relationship is seen in monkeys during CR where
the incidence of age-related diseases decreases while lifespan
increases [43,44]. CR is not a practical strategy to extend lifespan
in humans, but pharmacological agents are, and the rapamycin-
type compounds seem quite promising [4–6]. As promising as
rapamycin and related drugs are for improving human health and
extending lifespan, they may have unforeseen drawbacks and be
suitable only for individuals with specific genotypes. Hence, other
strategies are needed.
Sphingolipids regulate yeast lifespan
Our data show that down-regulating sphingolipid synthesis
produces an increase in the CLS of S. cerevisiae cells (Figure 2,
Figure 3, and Figure 7) and that part of this increase depends on
the Sch9 protein kinase (Figure S2 in Text S1, Figure 5, Figure 6,
and Figure 7A), an established regulator of lifespan. We show that
CLS can be increased by lowering sphingolipid synthesis via
manipulation of SPT, the initial enzyme in sphingolipid
biosynthesis (Figure 2, Figure 3, and Figure 7). We propose that
lowering SPT activity increases CLS, at least in part, by reducing
the concentration of LCBs thereby lowering the activity of Pkh1/2
and Sch9 which programs cells for an extended lifespan
(Figure 1A). This scenario is supported by data showing that
myriocin treatment or down-regulation of tetO7-LCB1 gene
expression diminishes Pkh1/2-dependent phosphorylation of
Sch9 residue T570, essential for activity (Figure 5) and reduces
phosphorylation of the Sch9 substrate Dot6 (Figure 5I). In
addition, as a surrogate for Sch9 activity in vivo, we measured
processes that play key roles in lifespan and are regulated by Sch9.
All processes including resistance to heat, oxidative and acetic acid
stress (Figure 2, Figure 3, Figure 6A and 6B), cell size (Figure S2 in
Text S1), mitochondrial oxygen consumption (Figure 6C), and
genome stability (Figure 6D and 6E) responded to down-
regulation of sphingolipid synthesis in a manner indicative of
reduced Sch9 activity.
Deletion of PKH2 was recently shown to extend CLS [34]. We
verified this finding (Figure 5A) and show that phosphorylation of
Sch9 T570 is reduced in pkh2D cells (Figure 5B). Finally, we show
that cells with low Pkh kinase activity are much more sensitive to
growth inhibition by myriocin or Dox than are cells with higher
Pkh activity (Figure 5D and Figure S4 in Text S1). Together these
data add further support for a signaling pathway comprised of
sphingolipidsRPkh1/2RSch9RCLS.
While most of our data suggest that down-regulating sphingo-
lipid synthesis increases lifespan by Sch9-dependent mechanisms,
the finding that myriocin causes a mobility shift in Sch9, indicative
of reduced phosphorylation, and increases the CLS of sch9D cells
argues for some aspects of CLS extension operating by Sch9-
independent mechanisms. Down-regulation of the protein kinase
A [45] pathway is the most likely way for sphingolipids to affect
lifespan independently of Sch9, since these two pathways have
been known to interact ever since the initial discovery of Sch9
[46]. Also, the pathways are known to interact in a way that
extends CLS, since ras2D sch9D double mutant cells have a longer
lifespan than the single mutants [30]. This interaction phenotype is
similar to what we find with myriocin treatment of sch9D cells
(Figure 7A). Recent publications have detected biochemical links
between the Pkh1/2-Sch9 and PKA pathways [24,25,47] and
these may explain how myriocin increases the lifespan of sch9D
cells, but further effort is needed to determine if this is actually the
case.
In addition to LCBs, complex sphingolipids (IPCs and perhaps
MIPCs) may be regulating CLS, since their concentration is
lowered along with LCBs when SPT activity is down-regulated
(Figure 4C, 4D, and 4E). A multi-membrane spanning protein
Nce102 has been proposed to sense complex sphingolipids and
negatively regulate Pkh1/2 [26]. According to this proposal, a
reduction in complex sphingolipids should increase Pkh1/2
activity by releasing Nce102-mediated down-regulation. As a
consequence, Sch9 activity should increase; however, this would
not enhance CLS and is contrary to our finding that reducing
sphingolipids decreases Sch9 activity. Thus, Nce102 is unlikely to
be mediating the increase in CLS that we observe.
Figure 5. Evidence for the sphingolipidRPkh1/2RSch9 pathway. (A) CLS of pkh2D cells (RCD1051) compared to parental PKH2 cells
(RCD956). Average survival values and statistical significance for eight replicate cultures (total cultures from two different assays) are shown. Statistical
significance is indicated for specific time points. These data are nearly identical to published data obtained using a different strain background and
culture conditions [34]. (B and C) Immunoblot analysis of Sch9 and P-T570 in the strains used (A) and grown from a starting A600 nm of 0.005 to a value
of 1. For each lane the Sch9 signal was normalized to the signal for the Vma2 internal standard (value shown below each lane) and then the P-T570
signal (value shown below the T-570 band) was normalized to this number. Average values are shown in parentheses. (D) Dilution assay (10-fold serial
dilution from left to right) for myriocin sensitivity of WT (15Dau/pRS315/pRS316), pkh1
ts pkh2D (INA106-3B/pRS316) and INA106-3B cells transformed
with pRS316-PKH1 or pRS316-PKH2. (E) Sch9 and P-T570 were quantified by immunoblotting of extracts made from four cultures of DBY746 cells
treated or not treated with myriocin (Myr, 400 ng/ml) while growing from a starting A600 nm of 0.005 to a value of 1. Normalized values were
calculated as described in (B). (F) The average of the P-T570 signals from (E) is plotted along with the statistical significance. (G) Sch9 and P-T570 were
measured in myriocin-treated or untreated WT (R1158) and tetO7-LCB1 (RCD956) cells as described in (B). (H) Sch9 and P-T570 were measured in Dox-
treated or untreated WT (R1158) and tetO7-LCB1 (RCD956) cells as described in (B). (I) Myriocin treatment reduces Sch9-mediated phosphorylation of
Dot6-5HA. RCD1052 cells transformed with the indicated plasmids were grown as described in (B) and immunoblots of extracts were probed with
anti-HA antibody or with antibody for the internal standard Vph1 protein. (J) Same blot as shown in panel (I) but reprobed for Sch9 T570
phosphorylation. The asterisk indicates a not specific band.
doi:10.1371/journal.pgen.1002493.g005
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activating Pkh1/2 kinase activity [27]. These authors found that
short-term, acute dose myriocin treatment of cells failed to reduce
Pkh1/2-mediated phosphorylation of residue T504 in the Ypk1
kinase. And recently, short-term, acute dose treatment of cells with
myriocin did not decrease Pkh1/2-mediated phosphorylation of
T570 in Sch9 [25]. In contrast to these results, we show that
lowering the rate of sphingolipid synthesis by long-term, low dose
myriocin treatment or down-regulation of LCB1 expression
reduces Pkh1/2-mediated phosphorylation of T570 (Figure 5)
and, in addition, myriocin treatment reduces phosphorylation of
the Sch9 substrate Dot6 (Figure 5I). These results clearly support
the idea that sphingolipids regulate lifespan by reducing Pkh1/2-
mediated phosphorylation of T570 thereby reducing Sch9 activity.
Further work is required to determine which sphingolipids control
Sch9 activity and CLS (Figure 1A).
Studies of the ISC1 gene also implicate sphingolipids in
controlling lifespan. Isc1 hydrolyzes the polar head group from
complex sphingolipids to yield ceramides. The CLS of isc1D cells is
reduced partly because of mitochondrial dysfunctions [48], but
CLS can be extended in these cells even beyond the wild-type
value by deleting the SIT4 gene. Sit4 is the catalytic subunit of a
PP2A-type protein phosphatase whose activity is down-regulated
by TORC1 but up-regulated by ceramides (Figure 1A). In our
experiments, enhancement of CLS by down-regulating sphingo-
lipid synthesis in both wild-type and sch9D cells may involve Sit4,
because reducing the abundance of IPCs, and perhaps MIPCs
(Figure 4), may lower the amount of ceramide generated by Isc1.
Figure 6. Down-regulating sphingolipid synthesis enhances CLS by Sch9-dependent mechanisms. (A) Doxycycline treatment enhances
resistance of tetO7-LCB1 (RCD956) and tetO7-SCH9 (RCD952) cells to acetic acid. Cells from CLS day 1, grown in the presence or absence of Dox
(300 ng/ml, were treated with acetic acid. (B) Myriocin treatment enhances resistance of DBY746 (WT) cells to acetic acid. Cells were grown and
treated with myriocin (Myr) as described in (A). The sch9D strain was PF102. (C) The rate of oxygen consumption was measured in WT (DBY746) or
sch9D (PF102) cells treated on not treated with myriocin (400 ng/ml). Cells were grown as described in panel B of Figure 5. Because cell volume is
affected by myriocin treatment and deletion of SCH9, we measured cell volumes and normalized the values to the volume of 10
6 WT cells grown
without myriocin treatment. Average values for four cultures and statistical significance are indicated. (D) Myriocin treatment (300 ng/ml) reduces the
frequency of Can
r mutations in sgs1D cells. Cells were grown in SDC medium (pH 4.5, 36iron). Values represent the average for triplicate cultures
started at an A600 nm of 0.05. Strains are: WT, RCD1009; sgs1D, RCD1010; sgs1D sch9D, RCD1011. (E) Myriocin treatment reduces the frequency of gross
chromosomal rearrangements in sgs1D cells. Strains, culture conditions are the same as described in (D).
doi:10.1371/journal.pgen.1002493.g006
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deletion of SIT4 (Figure 1A). Finally, other studies implicate
complex sphingolipids in CLS, since ipt1D and skn1D cells, which
lack the most complex sphingolipid M(IP)2C, have a slight increase
in CLS and deletion of both genes yields an additive increase in
CLS [49]. It remains to be determined how a reduction in
M(IP)2C increases CLS, but this effect is probably real as skn1D
cells ranked high in a survey of lifespan in the yeast single-deletion
strain set [1].
Sphingolipids have been implicated also in RLS. The first S.
cerevisiae gene found to regulate RLS, LAG1 (Longevity-Assurance
Gene 1) [50], was later shown to encode a component of ceramide
synthase which catalyzes ceramide synthesis from LCBs and fatty
acids (Figure S1 in Text S1) [51,52]. Deleting LAG1 increases RLS
but has no effect on CLS [1]. Since the mechanism for increased
RLS without increased CLS is unknown, it is difficult to relate
these data to our CLS data.
In cases where a decrease in LCBs has perturbed a cellular
process in yeast it has been possible to restore the process by adding
LCBs to the culture medium [53–55]. This strategy suggests that
exogenous PHS should prevent the increase in CLS produced by
Dox treatment of tetO7-LCB1 cells. In actuality, low levels of PHS
(10–500 nM) did not thwart the increase in CLS and higher doses
(10 mM) actually enhanced CLS. Exogenous PHS is likely to
enhance CLS by inducing the general stress response via activation
of genes with stress response elements (STREs) in their promoter, as
previously reported [53,56]. In addition, exogenous PHS is known
to down-regulate amino acid and other nutrient transporters in
yeast [57,58] and this is likely to increase lifespan since amino acid
or glucose deprivation enhance yeast lifespan [1,59].
Lifespan regulation by myriocin and CR
Because CR is the standard for judging interventions that
extend lifespan, we determined if myriocin enhances lifespan in
CR-treated cells. We found that myriocin treatment does enhance
CLS in cells grown under moderate (0.5% glucose, Figure S3 in
Text S1) or extreme CR (water) conditions (Figure 7B). These
results are similar to the recent finding that rapamycin treatment
increases the lifespan of caloric restricted Drosophila [3] and they
have implications for human health. For example, it may be
possible to reduce disease incidence and increase human lifespan
by combining a drug with low level CR or with a CR mimetic such
as rapamycin. Furthermore, a combination regime may reduce
disease incidence in genotypic backgrounds which are unrespon-
sive to single treatment regimes.
Sphingolipids and lifespan in multicellular eukaryotes
Increasing lifespan by using a pharmacological agent to down-
regulate sphingolipid synthesis may be applicable to other
organisms in addition to yeasts much as rapamycin treatment
has been used to down-regulate the TOR pathway and increase
lifespan in yeast, worms, flies and mice [1–3,10,18]. The
sphingolipids that regulate lifespan in yeast may not be present
in mammals and, thus, lifespan extension may require modulating
another type of mammalian sphingolipid [11]. Ceramides and
sphingosine-1-phosphate are the most widely appreciated sphin-
golipid signaling molecules in mammals [11,12]. Ceramides are
thought to promote age-related diseases since their concentration
increases with age in many mammalian cells and tissues where
they regulate processes that may control lifespan [60–64].
Recently long-chain hexosylceramides and lactosylceramides have
been implicate in aging and lifespan in mice and cultured human
cells [65]. The challenge will be to determine if mammalian
lifespan can be extended by preventing the increase in ceramides
or whether up or down-modulating the concentration of other
sphingolipids will extend lifespan. There is, however, precedent for
extending lifespan in multicellular eukaryotes through modulation
of sphingolipids: inactivation of the Dacer gene, which encodes an
Figure 7. Myriocin enhances CLS by mechanisms that are independent of Sch9 and caloric restriction. (A) CLS of sch9D cells (PF102) +/2
Myr treatment. Data represent the mean 6 SEM of survival (* p,0.05, ** p,0.01, No Myr vs 300 ng/ml Myr). (B) CLS of WT (DBY746) cells grown in
SDC medium (2% glucose, pH 4.5, 36iron) +/2 Myr for 3 days was measured. After 72 hrs of incubation (CLS day 1) the medium in half of the
cultures was switched to water (E-CR) while the other half were not switched to CR (NR). Water was replaced every third day with fresh water to
remove nutrients released from dead cells. Data represent the mean 6 SEM of viable cells in triplicate cultures (** p,0.01, No Myr vs 300 or 600 ng/
ml Myr, E-CR cultures).
doi:10.1371/journal.pgen.1002493.g007
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Drosophila [66].
As mutations and chromosomal rearrangements promote
mammalian tumor cell formation, our demonstration that
myriocin treatment reduces the rate of mutation and gross
chromosomal rearrangements in yeast (Figure 5D and 5E) could
lead to novel preventive measures and treatments for human
cancers and thereby enhance lifespan.
Materials and Methods
Yeast strains, media, and plasmids
Yeast strains used in our studies are listed in Table S1 in Text
S1. Viability assays were done by using YPD agar plates (2%
yeast extract, 1% peptone, 2% dextrose and 2% agar). For CLS
and stress resistance assays, cells were grown in SDC medium
supplemented with a 4-fold excess of the tryptophan, leucine,
uracil and histidine to avoid possible artifacts due to auxotrophic
deficiencies of the strain [30]. For initial experiments, SDC
medium was lightly buffered to pH 6.0 (1.6 gm NaH2PO4 N
H2O/liter), while in later experiments it was more strongly
buffered with succinic acid (200 mM, final pH 4.5). Initially the
concentration of iron in SDC medium was 1.23 mM( 1 6 yeast
nitrogen base) but in later experiments the concentration was
raised 3-fold to avoid iron-starvation and reduced viability. In
summary, SDC medium, pH 6.0, 16 iron, was used for the
experiments shown in Figure 1, Figure 2, and Figure 3A–3F,
while the same medium, but with 36 iron, was used for the
experiments shown in Figure 3H, Figure 4, and Figure 6A. For
the experiments shown in Figure 3G, 3H, Figure 5, Figure 6C–
6E, Figure 7, and Figures S2, S3, S4 in Text S1 the medium was
SDC, pH 4.5, 36iron.
The pRS315 and pRS316 vectors [67] were used to make
pRS315ADE2 by ligating a 2.3 Kb PstI-SpeI fragment carrying
ADE2 into the corresponding sites of pRS315. Similarly, a
genomic EcoRI-XhoI fragment was ligated to pRS316 cut with
the same enzymes to make pRS316-PKH1 and a genomic BamHI-
SalI fragment was ligated to pRS316 cut with the same enzymes to
make pRS316-PKH2. pLCB1-5 was made by ligating a 4 Kb
NruI-SacI chromosomal fragment containing LCB1 and its
promoter [68] to pRS315ADE2 digested with SacI and NaeI
(made blunt ended). pRS315-LCB2-B7 was made by ligating a
7K b BamHI chromosomal fragment containing LCB2 and its
promoter [69] to pRS315 digested with BamHI. The plasmid
encoding HA-tagged Dot6 has been described [36].
Lifespan assays
CLS was measured as previously described [30]. Drug
treatments were performed in medium containing a final
concentration of 0.3% ethanol (ethanol plus drug). This was
done be first adding a calculated volume of 95% ethanol to the
medium followed by diluting a stock solution of myriocin
(200 mg/ml in 95% ethanol, Sigma, # M1177) or doxycycline
(100 mg/ml in 50% ethanol, Sigma, # D9891) to yield the
desired concentration of drug (indicated in figure legends). Drugs
were stored at 220uC and warmed to room temperature before
dilution into medium, followed by thorough mixing. Cells grown
overnight at 30uC in SDC medium were diluted into 25 ml of
medium (125 ml flask) to give an initial A600 nm of 0.002 or
as indicated in figure legends. Cultures were incubated at 30uCi n
an air bath shaker (220 rpm) for three days and cell viability was
measured (CLS day 1) by diluting and spreading cells on YPD
plates. After 2–3 days of incubation at 30uC colonies were
counted and expressed a fraction of the day 1 value. Statistical
significance was determined by using the two-tailed Student’s
t-test.
Stress resistance and oxygen consumption assays
Cells grown in SDC medium for the time indicated in figure
legends were diluted to an A600 nm of 1.0 in K-phosphate buffer
(pH 6.0), treated with hydrogen peroxide for 60 min at room
temperature with mixing, serially diluted (10-fold), spotted onto
YPD plates, and incubated at 30uC for 2–3 days. For thermal
stress resistance, cells were serially diluted (10-fold dilution starting
with an A600 nm=1), spotted onto YPD plates, and incubated at
either 55uC (heat-shocked) or 30uC (control) for 45–180 min.
Plates were incubated for 2–3 days at 30uC. For acetic acid
resistance, cells from day 1 (72 hrs of incubation) of a CLS assay
were treated with acetic acid as specified in the legend to Figure 6
for 2 hours at 30uC, followed by dilution and plating on YPD
plates to measure colony forming units (CFUs). CFUs of the
treated samples were expressed as a percentage of the untreated
samples.
Oxygen consumption was measured on cells grown from an
A600 nm of 0.005 to 1 at which time the cell concentration was
quantified by counting cells in a Petroff-Hausser counting
chamber, cell size was measured as described in Supplemental
Information and oxygen consumption was measured by using an
Oxytherm System [38]. Data are expressed as nmol of oxygen
consumed per min per total volume of 10
6 DBY746 cells.
Age-dependent DNA damage measurements
The frequency of spontaneous canavanine-resistant mutants
(Can
r) mutants was measured by using a published assay [42].
Cells were grown as described for CLS experiments and assayed
for CFUs except that cultures were started at a density of 0.05
A600 nm units/ml and the SDC medium was buffered with
succinate (200 mM, pH 4.5) and contained 3.69 mM iron (36
normal). These changes were necessary to prevent parental cells
from dying so rapidly that they behaved like sgs1 mutant cells.
Mutant sgs1 cells were grown in medium containing 300 ng/ml of
myriocin. The frequency of Can
r mutants was measured on the
days indicated in Figure 6D. To identify Can
r mutants, a sample of
the culture was centrifuged and the cell pellet was washed once
with sterile water and plated on selection medium (SDC-ARG
supplemented with 60 mg/ml L-canavanine sulfate)s. After 3–4
days of incubation at 30uC, the colonies were counted and
expressed as the ratio to total viable cells. GCRs were assayed as
described previously [42]. Strains carried a URA3 cassette at the
HXT13 locus which is located 7.5 kb from the CAN1 gene towards
the telomeric of chromosome V. The experimental protocol was
similarly to the one for measuring Can
r mutations but the
frequency of simultaneous loss of CAN1 and URA3 was measured
by plating cells on SDC plates containing 1 mg/ml 5-fluoroorotic
acid (5FOA) and 60 mg/ml L-canavanine sulfate [70].
Analysis of LCBs, LCBPs, and complex sphingolipids
To extract LCBs and LCBPs, cells were grown as described for
CLS assays and at the indicated time points 10 A600 nm units of
cells were treated by slowly adding cold TCA to a final
concentration of 6%. After incubating on ice for 5 min, cells
were collected by centrifugation, washed twice with cold water,
and suspended in 500 ml of fresh 80 mM triethylamine (made in
HPLC grade absolute ethanol). Samples were sonicated in a water
bath for 5 min at 37uC, heated for 30 min at 65uC, centrifuged
and the supernatant fluid (150 ml) was transferred to an HPLC
sample vial insert. AQC (6-aminoquinolyl-N-hydroxysuccinimidyl
carbamate) reagent (30 ml) was added and samples were treated at
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1.5 N KOH (made in MeOH) and incubation at 37uC for 30 min.
The pH was adjusted by adding 20 ml of 1.74 M acetic acid (made
in MeOH) and 40 ml of the sample were assayed by HPLC [71].
Complex sphingolipids were analyzed as described previously
[72] except for three changes. First, cells were grown in SDC
medium (pH 6, 3.69 mM Fe) from 0.005 to 1 A600 nm units to
produce uniform radiolabeling. Second, the concentration of
[2-
3H]myoinositol (American Radiochemicals, Inc., catalog
#ART116) in the growth medium was 40 mCi/ml. Finally, each
lane on the thin-layer plate contained 20 mL of non-radioactive
yeast sphingolipids (0.5 mg/ml), which after charring, were used
to verify the location of radioactive sphingolipids.
Protein extraction and Western blotting analysis
Cells were grown as described for a CLS assay and cell-free
yeast extracts were prepared by using a modified published
procedure [73]. Ten A600 nm units of cells were treated with cold
TCA as described above, suspended in 400 ml of water followed by
the addition of 400 ml of 0.2 M NaOH. Thoroughly mixed
samples were incubated 5 min at room temperature, concentrated
by centrifugation and suspended in 200 ml of lysis buffer (0.06 M
Tris-HCl, pH 6.8, 5% glycerol, 2% SDS, 1% b-mercaptoethanol).
After heating at 95uC for 5 min, samples were centrifuged and the
protein concentration of the supernatant fluid was determined by
using the DC protein assay kit (Bio-Rad Laboratories). Samples
(50 mg of protein) electrophoresed on a 9% SDS-PAGE gel were
transferred for 1.5 hours onto a PVDF membrane (Millipore
Immobilon) by using a Bio-Rad semi-dry transfer system. For the
blots shown in Figure 5I and 5J the acrylamide-bisacrylamide ratio
was changed from the normal 37.5:1 ratio to 172:1. Membrane
blocking and antibody binding were done in TBST (20 mM Tris,
150 mM NaCl, 0.1% Tween-20, pH 7.5) containing 5% nonfat
dry milk. Membranes were incubated for 2 hrs at room
temperature with custom made polyclonal rabbit anti-Sch9
antibodies (Batch 2872, 1:1000, OpenBiosystems), phosphor-
specific anti-Sch9T570 antibodies (1:10,000 dilution) [20], anti-
HA antibodies (clone 3F10, 1:5000, Roche) or commercial
monoclonal mouse anti-Vma2 (1:3,000 dilution) or anti-Vph1
(1:1000 dilution) antibodies (Molecular Probes). Other antibodies
included alkaline phosphatase-linked anti-rabbit or anti-mouse
IgG (1:5000, Sigma-Aldrich). Fluorescent signals from membranes
exposed to an ECF substrate (Amersham Biosciences) were
analyzed by using a PhosphorImager (Amersham Biosciences)
and quantified by using ImageQuaNT Software.
Supporting Information
Text S1 Supporting information, including supporting figures,
table, and references. Figure S1: Outline of sphingolipid
metabolism in Saccharomyces cerevisiae. Metabolic intermediates
and complex sphingolipids are shown in bold font, genes are
shown in italics and enzyme names are in regular lettering.
Structures of compounds have been presented previously [74,75].
Figure S2: Myriocin treatment decreases cell size. DBY746 cells
were grown with and without myriocin (Myr) as in a CLS assay
using SDC medium (pH 4.5, 3X iron). After 72 hrs of incubation,
cells were stained directly with Calcofluor white M2R (25 m/ml)
and photographed at room temperature by using a Nikon Eclipse
E600 fluorescence microscope equipped with a Plan Apo 1006
1.40 oil immersion objective, a SPOT RT 9.0 Monochrome-6
camera and SPOT basic software. For measurements, we
excluded extremely large or small cells and cell diameter was
calculated by measuring and averaging the long and short axes
(perpendicular to each other) of each cell as described previously
[30]. The median diameter for one hundred cells is indicated by a
horizontal bar in the scatter plot. Figure S3: CLS of WT
(DBY746) cells grown in SDC medium (pH 4.5, 3X iron) with CR
(0.5% glucose) or without CR (NR, 2% glucose) +/2 myriocin
(Myr) treatment. Data represent the mean 6 SEM of survival (*
p,0.05, ** p,0.01, No Myr vs 450 or 600 ng/ml Myr, CR
cultures). Figure S4: Sphingolipids activate the Pkh1/2 protein
kinases. (A) Growth sensitivity was measured by diluting cells from
CLS day 1 (10-fold serial dilution from left to right), spotting onto
YPD plates containing the indicated concentration of myriocin,
and incubating 3 days at 30 uC. Strains are: WT (R1158, LCB1),
tetO7-LCB1 (RCD956), tetO7-LCB1/pkh1D (RCD1048), and
tetO7-LCB1/pkh2D (RCD1051). (B) Same strains as used in A,
but spotted onto YPD plates containing Dox. Table S1: Strains
used in this study.
(DOCX)
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